T cells are the body’s natural immunedefense for fighting viral infections
At ViraCyte, we believe that no patient should ever suffer or die from viral infections after their transplant. This is our company’s first concern: to prevent or cure viral infections in patients with weakened immune systems
Viralym-C (Cytomegalovirus-specific T cells)
This year in the United States and Europe, over 30,000 patients will receive a hematopoietic stem cell transplantation (HSCT). Of these, over 10,000 will experience a severe viral infection post-transplant.
Our mission is to safely and effectively treat viral infections that attack people with weakened immune systems.
ViraCyte™ products include:Viralym: “ready to administer” T cell products to treat patients with active infectionPrelym: a personalized product prepared from the HSCT donor that can be used to prevent viral infections
Together, Viralym and Prelym comprise a full spectrum of solutions to eliminate infections after HSCT.